Market Value Weighted

The Sibutramine Cardiovascular Outcome Trial (SCOUT), a post-marketing research study, showed that the weight loss drug sibutramine, which was approved for use in the market in 1997, increased the risk of serious cardiovascular complications compared to placebo. The results of the study were published in the September 2, 2010 issue of the New England Journal of Medicine. More than 10,000 overweight or obese men and women over the age of 55 with pre-existing cardiovascular disease and/or diabetes participated in the study. They were randomized, took either sibutramine or placebo and were followed up for around three years.

Sibutramine is currently being used by around 100,000 people in the USA for weight loss. Compared to its possible risks for cardiovascular complications, its benefits for moderate weight reduction are outweighed. The drug acts as an appetite suppressant and is taken by mouth at a dose of 10 mg per day as a single dose. It is currently known under brand names like Meridia, Sibutrex and Reductil.

The FDA has therefore advised that patients stop taking the drug, and for physicians to stop prescribing it. Although there are still no known withdrawal effects from the drug and long term effects, stopping its intake has been shown to decrease its adverse effects. The drug has been suspended from marketing in Europe since January 2010 after a six-year study revealed its harmful effects.

• Transactional Marketing Partners

• Dma Marketing Term

• Acme Book Guest Market

  Acme manufactures a wide range of air movement products for the new construction market, including applications for industrial, institutional and ...

• Robinsons Karate School Newmarket

• Northern Virginia Christmas Market